Case 9. A New TRIO to Reduce ART Complexity

A 62-year-old patient with HIV for ~40 yrs presents on the life-saving TRIO regimen after a beloved care provider retires. Will a switch improve his quality of life? Eileen and Chris suspect that a change to a once-a-day regimen with fewer pills will maintain his viral suppression and make life easier, but the TRIO regimen inspires dedication in many long-term patients. Would he be open to a switch? Would it confer other benefits? Listen as Eileen and Chris consider the necessity of switch and plot a treatment course.References and Resources Cited:Paton NI, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 2022 Jun;9(6):e381-e393. Epub 2022 Apr 20. PMID: 35460601.University of Liverpool HIV Drug Interactions: Interaction CheckerStanford HIV Drug Resistance DatabaseRelated NYSDOH AIDS Institute Clinical Guidelines: Second-Line ART After Treatment Failure or for Regimen SimplificationHIV Resistance AssaysVirologic and Immunologic Monitoring in HIV CarePrimary Care for Adults With HIV and Guidance: Addressing the Needs of Older Patients in HIV Care